What is the approximate latest market price of lorlatinib in 2025?

As of2025, lorlatinib (Lorlatinib, also known as lorlatinib) has been officially launched in mainland China. It has been officially launched on the market and has been included in the national medical insurance directory. It is mainly used for the targeted treatment of ALK positive advanced non-small cell lung cancer (NSCLC). Because of its excellent efficacy in treating drug-resistant mutations and central nervous system metastasis, it is widely used in first-line or multi-line treatment options. However, despite being included in medical insurance, the price of lorlatinib in China is still relatively high, generally between 10,000 and 20,000 yuan. The actual price varies slightly depending on the region, medical insurance policies and drug purchase channels.

According to the latest market information, domestic patients can enjoy medical insurance reimbursement when purchasing drugs in regular hospital pharmacies or designated platforms, but the reimbursement ratio is closely related to the medical insurance policy of the patient's location. Usually, after medical insurance reimburses the patient, the out-of-pocket expenses still cost more than several thousand yuan. It is recommended that patients consult the pharmacy department of their hospital or the Medical Insurance Bureau before purchasing drugs to learn whether there are specific local policies such as Category B reimbursement, secondary reimbursement, and targeted drug assistance to minimize the financial burden.

In overseas markets, multiple versions of lorlatinib are also on sale. The original drug was developed by Pfizer and is currently sold in Türkiye, Hong Kong and other places. Among them, the price of the Turkish version of the original drug is relatively low, about 7,000 yuan per box, and is favored by many domestic patients. The price of original research drugs in Hong Kong, China, is relatively high, about 3 yuan, which falls into the price range of high-end channels. For some patients who do not meet the conditions for medical insurance or who want to purchase drugs on their own, obtaining overseas original drugs through cross-border pharmacies and purchasing platforms is an alternative, but it is important to ensure that the channels are legal and the drugs are authentic.

In addition, in some countries with relatively open medical resources, such as Laos and Bangladesh, multiple versions of the generic drug lorlatinib have appeared, and the price is more affordable, generally around 1,000 yuan per box. Although these generic drugs are low in price, their ingredients and dosage forms are basically the same as those of the original drugs, and many patients report that their efficacy is comparable. Although generic drugs may not be approved for marketing in China, some patients will obtain them through international pharmacies or cross-border medical channels. However, you need to be extremely cautious when using such drugs, and they must be taken under the guidance of a professional doctor to ensure both safety and efficacy.

Reference materials:https://www.drugs.com/